Profibrotic Molecules Are Reduced in CRISPR-Edited Emery–Dreifuss Muscular Dystrophy Fibroblasts

• Published in: Cells (Basel, Switzerland) Vol. 14; no. 17; p. 1321
• Main Authors: Cattin, Eleonora, Schena, Elisa, Mattioli, Elisabetta, Marcuzzo, Stefania, Bonanno, Silvia, Cavalcante, Paola, Corradi, Federico, Benati, Daniela, Farinazzo, Giorgia, Cattaneo, Marco, De Sanctis, Veronica, Bertorelli, Roberto, Maggi, Lorenzo, Giannotta, Melania, Pini, Antonella, Vattemi, Gaetano, Cassandrini, Denise, Cavallo, Marco, Manferdini, Cristina, Lisignoli, Gina, Fontana, Beatrice, Pace, Ilaria, Bruno, Claudio, Roncarati, Roberta, Fiorillo, Chiara, Ferracin, Manuela, Schirmer, Eric C., Recchia, Alessandra, Lattanzi, Giovanna
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 27.08.2025
• Subjects: Actin; Biopsy; Cardiomyopathy; Cell culture; Connective tissue growth factor; CRISPR; CRISPR-Cas Systems - genetics; CRISPR/Cas gene editing; Data analysis; Dilated cardiomyopathy; EDMD; emerin; Fibroblasts; Fibroblasts - metabolism; Fibroblasts - pathology; Fibrosis; Gene Editing; Genes; Genetic aspects; Homeostasis; Humans; Lamin Type A - genetics; Lamin Type A - metabolism; laminopathies; MicroRNA; MicroRNAs; MicroRNAs - genetics; MicroRNAs - metabolism; miRNA; miRNA profiling; Muscle proteins; Muscular dystrophy; Muscular Dystrophy, Emery-Dreifuss - genetics; Muscular Dystrophy, Emery-Dreifuss - metabolism; Muscular Dystrophy, Emery-Dreifuss - pathology; Mutation; Mutation - genetics; Myoblasts; Myofibroblasts - metabolism; Myofibroblasts - pathology; Pathogenesis; Phenotypes; Smooth muscle; Transforming growth factors; Vascular endothelial growth factor; Italy; Iowa; United States; Massachusetts; Basel Switzerland; United States > US; Switzerland; Germany; miRNA profiling; fibrosis; emerin; laminopathies; EDMD; CRISPR/Cas gene editing
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells14171321

Emery–Dreifuss muscular dystrophy (EDMD) is caused by mutations in EMD, LMNA, SYNE1, SYNE2, and other related genes. The disease is characterized by joint contractures, muscle weakening and wasting, and heart conduction defects associated with dilated cardiomyopathy. Previous studies demonstrated the activation of fibrogenic molecules such as TGFbeta 2 and CTGF in preclinical models of EDMD2 and increased secretion of TGFbeta 2 in patient serum. A wide screening of patient cells suggested fibrosis, metabolism, and myogenic signaling as the most affected pathways in various EDMD forms. In this study, we show that alpha-smooth muscle actin-positive myofibroblasts are overrepresented in patient fibroblast cultures carrying EMD, LMNA, or SYNE2 mutations, and profibrotic miRNA-21 is upregulated. Upon CRISPR/Cas correction of the mutated EMD or LMNA sequence in EDMD1 or EDMD2 fibroblasts, respectively, we observe a reduced expression of fibrogenic molecules. However, in patient myoblasts, neither fibrogenic proteins nor miRNA-21 were upregulated; instead, miRNA-21-5p was downregulated along with muscle-specific miRNA-133b and miRNA-206, which have a crucial role in muscle cell homeostasis. These observations suggest that the conversion of laminopathic fibroblasts into a profibrotic phenotype is a determinant of EDMD-associated muscle fibrosis, while miRNA-206-dependent defects of laminopathic myoblasts, including altered regulation of VEGF levels, contribute to muscle cell deterioration. Notably, our study provides a proof-of-principle for the application of gene correction to EDMD1 and EDMD2 and presents EDMD1 isogenic cells that exhibit an almost complete rescue of a disease-specific miRNA signature. These cells can be used as experimental models for studying muscular laminopathies.